May 2, 2013
By:
Nathan Jessop
Drug companies team up with INTERPOL to keep counterfeit medicines off the Internet and out of the hands of patients.
|
The outlook of the European biotech sector may not be as bleak as apparently believed despite the current economic climate.
Apr 2, 2013
By:
Nathan Jessop
The outlook of the European biotech sector may not be as bleak as apparently believed despite the current economic climate, but compared with their US rivals, biotech companies are still struggling to attract investors and secure funding.
|
Has Europe's Innovative Medicines Initiative been successful in alleviating concerns regarding the region?s levels of pharmaceutical innovation?
Mar 1, 2013
By:
Nathan Jessop
Has Europe's Innovative Medicines Initiative been successful in alleviating concerns regarding the region?s levels of pharmaceutical innovation?
|
|
The ongoing economic crisis in Europe has accelerated healthcare cost-containment measures targeting the price of pharmaceuticals, but the pharma industry is not giving in without a fight.
Feb 1, 2013
By:
Nathan Jessop
The ongoing economic crisis in Europe has accelerated healthcare cost-containment measures targeting the price of pharmaceuticals, but the pharma industry is not giving in without a fight.
|
|
Vaccine manufacturing was predicted in 2008 to be on the cusp of a golden era, but instead the industry has experienced cost pressures, high-profile liability cases and production setbacks.
Jan 1, 2013
By:
Nathan Jessop
Vaccine manufacturing was predicted in 2008 to be on the cusp of a golden era, but instead the industry has experienced cost pressures, high-profile liability cases and production setbacks.
|
|
Dec 2, 2012
By:
Nathan Jessop
Nathan Jessop reviews the pharmaceutical industry's experience with the first year of Germany?s new pricing policy.
|
|
The pharmaceutical industry is under pressure to deliver new therapies for Alzheimers disease, but the regulatory bureaucracy in Europe coupled with the demand for lower-priced medicines continues to hinder efforts in innovation.
Nov 2, 2012
By:
Nathan Jessop
Regulatory bureaucracy in Europe coupled with the demand for lower-priced medicines continues to hinder efforts in innovation for Alzheimer's disease.
|
|
Oct 1, 2012
By:
Nathan Jessop
EMA has been increasing its interactions with other regulatory agencies across the globe. The agency's most talked about collaboration is with FDA, but EMA has also been intently focused on bolstering its relationship with its counterparts in Japan, India and Russia.
|
|
Regulators in both the EU and the US have attempted to stimulate paediatric-drug development with incentives offering extended periods of patent protection, but are these actions having the desired effects?
Sep 1, 2012
By:
Nathan Jessop
Regulators in both the EU and the US have attempted to stimulate paediatric-drug development with incentives offering extended periods of patent protection, but are these actions having the desired effects?
|
|
